Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
18.37
-0.40 (-2.13%)
At close: Oct 8, 2025, 4:00 PM EDT
19.22
+0.85 (4.63%)
After-hours: Oct 8, 2025, 5:30 PM EDT

Neuphoria Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 20212016 - 2020
Period Ending
Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 2016 - 2020
Net Income
-0.37-15.49-21.38-14.99-6.52
Upgrade
Depreciation & Amortization
0.660.660.660.761.28
Upgrade
Other Amortization
----0.19
Upgrade
Loss (Gain) From Sale of Assets
---00.02
Upgrade
Stock-Based Compensation
0.160.811.351.950.98
Upgrade
Other Operating Activities
0.12-2.120.151.15-2.82
Upgrade
Change in Accounts Receivable
0.110.34.14-0.030.03
Upgrade
Change in Accounts Payable
-0.920.80.370.68-0.05
Upgrade
Change in Other Net Operating Assets
0.770.490.21-4.381.39
Upgrade
Operating Cash Flow
0.08-14.68-14.64-14.99-5.65
Upgrade
Capital Expenditures
----0-0
Upgrade
Sale of Property, Plant & Equipment
---0.120.03
Upgrade
Investment in Securities
---0.3-0.09
Upgrade
Other Investing Activities
---0.010
Upgrade
Investing Cash Flow
---0.43-0.06
Upgrade
Long-Term Debt Repaid
----0.12-8.9
Upgrade
Net Debt Issued (Repaid)
----0.12-8.9
Upgrade
Issuance of Common Stock
1.5310.113.8622.6632.87
Upgrade
Other Financing Activities
-5--3.94-0.31
Upgrade
Financing Cash Flow
1.5315.113.8618.623.66
Upgrade
Foreign Exchange Rate Adjustments
-00.08-0.24-0.55-0.01
Upgrade
Net Cash Flow
1.60.5-11.023.4917.93
Upgrade
Free Cash Flow
0.08-14.68-14.64-14.99-5.65
Upgrade
Free Cash Flow Margin
0.49%---359.30%-812.46%
Upgrade
Free Cash Flow Per Share
0.05-17.64-0.01-0.01-0.01
Upgrade
Cash Interest Paid
0.020.03-0.030.54
Upgrade
Cash Income Tax Paid
-0.05---
Upgrade
Levered Free Cash Flow
0.46-7.96-6.7-8.19-2.14
Upgrade
Unlevered Free Cash Flow
0.46-7.96-6.7-8.18-1.66
Upgrade
Change in Working Capital
-0.51.454.58-3.861.22
Upgrade
Updated Sep 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q